The Linked Clinical Trials Meeting

This week will see the Linked Clinical Trials committee meet again for its annual assessment and evaluation of multiple drugs and compounds with the potential to modify Parkinson's.Read more

Dr Simon Stott joins The Cure Parkinson's Trust

The Cure Parkinson's Trust is delighted to welcome Dr Simon Stott as the newly appointed Deputy Director of Research. Simon joins the team on 1st October 2018.Read more

Webinar Discussion: “How Does Parkinson’s Disease Begin? Perspectives on Neuroanatomical Pathways, Prions, and Histology.”

Re-watch the second of our new quarterly webinar series in partnership with Parkinson’s Movement and the Journal of Parkinson’s Disease .Read more

Rallying to the Challenge 2018 – Facebook Live

Tune into a live panel discussion broadcast from this year's Rallying to the Challenge meeting on September 27 discussing non motor symptoms in Parkinson’s with perspectives from PwP’s and researchers on the panel.Read more

The Cure3 Exhibition

The Cure Parkinson’s Trust, in association with Bonhams and Artwise, is delighted to announce the second edition of Cure3, an acclaimed selling exhibition devised to raise awareness of and funds for Parkinson’s research.Read more

Rapsodi Study

Rapsodi is an internet based cohort study designed to assess those with mutations in the GBA gene for the earliest signs of Parkinson’s disease. Its eventual aim is to provide a platform for targeting neuroprotective medication to those who are developing or at a high risk of developing Parkinson’s disease.Read more

Denali Announce Positive LRRK2 Trial Results with Advance to Phase 1b Trial

Denali Therapeutics has announced positive clinical results from their LRRK2 inhibitor programme and their advance to a Phase 1b trial in Parkinson’s patients with and without a genetic LRRK2 mutation.Read more

Cure3 2018: Art for Parkinson's

We are delighted that Cure3 is taking place again this year! Over 80 leading artists and architects will create exclusive works which will be sold at this unique selling exhibition...Read more

Parkinson’s Movement Awarded Wellcome Public Engagement Fund Grant

The Cure Parkinson's Trust (CPT) is delighted that Parkinson's Movement (PM) has secured a Wellcome Public Engagement Fund grant from The Wellcome Trust which will support the development of audio/visual content on the PM website over the next two years.Read more

Drug Repurposing in Parkinson's

Given the number of failures and the ever-increasing costs and lengthy processes for drug development, our attention continues to be focused on utilising existing compounds approved for other conditions as novel treatments for Parkinson’s...Read more

R S Macdonald Trust Awards Grant for Further Stem Cell Research

The Cure Parkinson’s Trust is delighted that the R S Macdonald Charitable Trust has awarded a grant to co-fund the continuing dopamine replacement stem cell research of Dr Tilo Kunath at the MRC in Edinburgh.Read more

Trial Design for Parkinson's Disease Modification

Helen Matthews, Deputy CEO, attended a recent summit in New York focused specifically on trial design for disease modification organised by The Michael J. Fox Foundation for Parkinson’s Research.Read more

Kyoto Team Begin Cell Replacement Trial In Parkinson's

Professor Jun Takahashi & colleagues at the University of Kyoto Japan have announced that they are to start the world’s first clinical trial of cells derived from induced pluripotent stem cells in people with Parkinsons...Read more

Cell Replacement Therapies for Parkinson's - Dr Tilo Kunath

Dr Tilo Kunath is working with cells derived from people with Parkinson's to understand the underlying causes of the condition; to test drugs that might treat it and to replace those cells which are lost.Read more

Stem Cell Therapies - Research Update

When diagnosed, people with Parkinson’s have often had the disease for years and have lost over half of the dopamine producing cells in their brain. Now scientists are searching for a way to replace these nerve cells.Read more

LRRK2 May Play a Role in Idiopathic Parkinson's

Abnormally increased kinase activity due to mutations in the leucine-rich repeat kinase 2 (LRRK2) gene is the cause of Parkinson’s in about 3 to 4% of people with Parkinson's however researchers have found that independent of any mutations, LRRK2 may also play a role in idiopathic Parkinson's.Read more

AMRC - Spotlight Report on Healthy Ageing

The AMRC's 'Spotlight Report on Healthy Ageing' is highlighting the work medical research charities are doing to prevent disease and promote health in the UK's ageing society...Read more

Peptron Announces Data of Sustained Release Exendin-4 for PD

Peptron has developed a novel form of the GLP-1 agonist SR-exenatide that effectively crosses the blood-brain barrier and provides sustained release of the neuroprotective peptide in the brain...Read more

Herantis Announces Non-Invasive Treatment Plan of CDNF

Herantis Pharma has announced the initiation of a non-invasive CDNF development programme to broaden the application of CDNF in Parkinson's.Read more

The Lixisenatide Trial

Another trial in the promising GLP-1 cohort, this study will evaluate the effect of lixisenatide versus placebo on the progression of motor disability in people with early Parkinson's in order to assess its potential disease-modifying effect.Read more

The Liraglutide Trial

This GLP-1 receptor agonist study will test the efficacy and safety of liraglutide in the treatment of people with idiopathic Parkinson's (PD)...Read more